Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fidelity National Information Servcs Inc (FIS) vs Summit Therapeutics Inc (SMMT) Price & Performance

Fidelity National Information Servcs IncTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Fidelity National Information Servcs Inc vs Summit Therapeutics Inc — how do they compare? Fidelity National Information Servcs Inc trades at $41.95 (market cap $22.05B), while Summit Therapeutics Inc trades at $15.05 (market cap $12.06B). The key difference: Fidelity National Information Servcs Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

FISSMMT
Market Cap
$22.05B$12.06B
Sector
TechnologyHealth
52-Week High
$72.77$26.98
52-Week Low
$37.72$12.55
Enterprise Value
$42.56B$11.39B
Dividend Yield
4.12%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fidelity National Information Servcs Inc

FIS trades at $42.10, down 0.96% with bearish technical signals. The company shows improving fundamentals with Q2 2026 earnings beat and 5.3% revenue growth, though it lowered full-year guidance. Valuation appears attractive with P/E of 6.57 and P/S of 1.82. Recent expansion into APAC markets and treasury software recognition provide growth catalysts. Cash flow improved significantly from 2025's negative $1.35B to projected positive $188M for 2026.

FIS presents a mixed outlook with strong banking solutions growth offset by capital markets weakness. The 19% upside to consensus price target of $50.18 offers potential, but execution risks remain given the guidance reduction. Investors should weigh the attractive valuation against operational challenges in achieving sustained profitability improvement.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.

Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.

Returns comparison

Trailing returns across standard periods

About Fidelity National Information Servcs Inc

Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.

Read more on FIS

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT